Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation: Analysis of Pooled Data From Five Randomized Controlled Trials

Archives of Internal Medicine

Volumn 154, Issue 13, 1994, Pages 1449-1457

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD PRESSURE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE;

AGED; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 0028244264     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1994.00420130036007     Document Type: Article

References (24)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-178.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505.
5. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-1412.
7. Laupacis A, Connolly SJ, Gent M, Roberts RS, Cairns J, Joyner C. How shouldthe results from completed studies influence ongoing clinical trials? the CAFA study experience. Ann Intern Med. 1991;115:818.
8. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;B34:187.
9. Frome EL. Analyses of rates using Poisson regression models. Biometrics. 1983; 39:665-674.
10. Predictors of Thromboembolism in Atrial Fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
11. Predictors of Thromboembolism in Atrial Fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
12. Bennett JD, for the Board on Health Sciences Policy of the Institutes of Medicine. Inclusion of women in clinical trials: policies for population subgroups. N Engl J Med. 1993;329:288-291.
13. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs: a change in food and drug administration policy. N Engl J Med. 1993;329: 292-296.
14. Angell M. Caring for women’s health: what is the problem? N Engl J Med. 1993;329:271-272.
15. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298:789.
16. Moulton AW. Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med. 1991;91:156-161.
17. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol. 1990; 65:1112-1116.
18. Roy D, Marchand E, Gagné P, Chabot M, Carter R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-1043.
19. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986;17:622-626.
20. Sherman DG, Goldman L, Whiting RB, Jurgensen K, Kaste M, Easton JD. Thromboembolism in patients with atrial fibrillation. Arch Neurol. 1984;41:708-710.
21. ‘Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
22. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
23. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin vs aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
24. Major Ongoing Stroke Trials. Stroke. 1994;25:541-545.